DALLAS and FORT WORTH, Texas, June 12, 2019 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary modified-release drug delivery and orally disintegrating tablet (ODT) technology platforms, today announced that Jerry McLaughlin, its Chief Executive Officer, will present a company overview at two upcoming conferences in June.
- The JMP Securities Life Sciences Conference on Wednesday, June 19, 2019 at 12:00 p.m. ET in New York, NY.
- The BMO 2019 Prescriptions for Success Healthcare Conference on Tuesday, June 25, 2019 at 11:00 a.m. ET in New York, NY.
A live webcast of both presentations will be available on the Investor Relations page of the company’s website at http://investors.neostx.com/. Following each presentation, a replay of the webcast will be available on Neos’ website for 30 days.
About Neos Therapeutics
Neos Therapeutics, Inc. (NASDAQ: NEOS) is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), and Adzenys-ER® (amphetamine) extended-release oral suspension (see Full Prescribing Information, including Boxed WARNING), all for the treatment of ADHD, are three approved products using the Company’s extended-release technology platform. Additional information about Neos is available at www.neostx.com.
Richard I. Eisenstadt
Chief Financial Officer
Stern Investor Relations, Inc.
Neos Therapeutics, Inc.